These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34723071)

  • 1. First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases.
    Servais L; Camino E; Clement A; McDonald CM; Lukawy J; Lowes LP; Eggenspieler D; Cerreta F; Strijbos P
    Digit Biomark; 2021; 5(2):183-190. PubMed ID: 34723071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
    Servais L; Yen K; Guridi M; Lukawy J; Vissière D; Strijbos P
    J Neuromuscul Dis; 2022; 9(2):335-346. PubMed ID: 34958044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.
    Rabbia M; Guridi Ormazabal M; Staunton H; Veenstra K; Eggenspieler D; Annoussamy M; Servais L; Strijbos P
    J Neuromuscul Dis; 2024; 11(3):701-714. PubMed ID: 38640165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials.
    Haberkamp M; Moseley J; Athanasiou D; de Andres-Trelles F; Elferink A; Rosa MM; Magrelli A
    Neuromuscul Disord; 2019 Jul; 29(7):514-516. PubMed ID: 31272741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-led development of digital endpoints and the use of computer vision analysis in assessment of motor function in rare diseases.
    Ferrer-Mallol E; Matthews C; Stoodley M; Gaeta A; George E; Reuben E; Johnson A; Davies EH
    Front Pharmacol; 2022; 13():916714. PubMed ID: 36172196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the Benefits of Digital Biomarkers and Technology-Based Study Endpoints in Clinical Trials: Project Moneyball.
    Mori H; Wiklund SJ; Zhang JY
    Digit Biomark; 2022; 6(2):36-46. PubMed ID: 35949224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].
    Bernert G; Hahn A; Köhler C; Meyer S; Schara U; Schlachter K; Trollmann R; Walter MC
    Nervenarzt; 2021 Apr; 92(4):359-366. PubMed ID: 33215271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment.
    Le Moing AG; Seferian AM; Moraux A; Annoussamy M; Dorveaux E; Gasnier E; Hogrel JY; Voit T; Vissière D; Servais L
    PLoS One; 2016; 11(6):e0156696. PubMed ID: 27271157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy.
    Larkindale J; Abresch R; Aviles E; Bronson A; Chin J; Furlong P; Gordish-Dressman H; Habeeb-Louks E; Henricson E; Kroger H; Lynn C; Lynn S; Martin D; Nuckolls G; Rooney W; Romero K; Sweeney L; Vandenborne K; Walter G; Wolff J; Wong B; McDonald CM; Duchenne Regulatory Science Consortium Imaging-Dmd Consortium And The Cinrg Investigators MO
    PLoS Curr; 2017 Jan; 9():. PubMed ID: 28228973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.
    Kennedy RA; Carroll K; McGinley JL; Paterson KL
    J Foot Ankle Res; 2020 Mar; 13(1):10. PubMed ID: 32122377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.
    Ricotti V; Selby V; Ridout D; Domingos J; Decostre V; Mayhew A; Eagle M; Butler J; Guglieri M; Van der Holst M; Jansen M; Verschuuren JJGM; de Groot IJM; Niks EH; Servais L; Straub V; Voit T; Hogrel JY; Muntoni F
    Neuromuscul Disord; 2019 Apr; 29(4):261-268. PubMed ID: 30852071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability and validity of the Thai version of the Pediatric Quality of Life inventory™ 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy.
    Thongsing A; Likasitwattanakul S; Sanmaneechai O
    Health Qual Life Outcomes; 2019 May; 17(1):76. PubMed ID: 31046775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital PCR quantification of miR-30c and miR-181a as serum biomarkers for Duchenne muscular dystrophy.
    Llano-Diez M; Ortez CI; Gay JA; Álvarez-Cabado L; Jou C; Medina J; Nascimento A; Jimenez-Mallebrera C
    Neuromuscul Disord; 2017 Jan; 27(1):15-23. PubMed ID: 27979502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy.
    Mazzone ES; Vasco G; Palermo C; Bianco F; Galluccio C; Ricotti V; Castronovo AD; Mauro MS; Pane M; Mayhew A; Mercuri E
    Dev Med Child Neurol; 2012 Oct; 54(10):879-85. PubMed ID: 22713125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy.
    Straub V; Balabanov P; Bushby K; Ensini M; Goemans N; De Luca A; Pereda A; Hemmings R; Campion G; Kaye E; Arechavala-Gomeza V; Goyenvalle A; Niks E; Veldhuizen O; Furlong P; Stoyanova-Beninska V; Wood MJ; Johnson A; Mercuri E; Muntoni F; Sepodes B; Haas M; Vroom E; Aartsma-Rus A
    Lancet Neurol; 2016 Jul; 15(8):882-890. PubMed ID: 27302365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy.
    Ke Q; Zhao ZY; Mendell JR; Baker M; Wiley V; Kwon JM; Alfano LN; Connolly AM; Jay C; Polari H; Ciafaloni E; Qi M; Griggs RC; Gatheridge MA
    World J Pediatr; 2019 Jun; 15(3):219-225. PubMed ID: 30904991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.
    Gissy JJ; Johnson T; Fox DJ; Kumar A; Ciafaloni E; van Essen AJ; Peay HL; Martin A; Lucas A; Finkel RS;
    Neuromuscul Disord; 2017 Oct; 27(10):905-910. PubMed ID: 28739181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.